FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO:04:054 | Clinical efficacy and drug retention rate of upadacitinib in patients with axial spondyloarthritis: results from a single-center observational study Simona Buonanno1, Carla Gaggiano1, Caterina Baldi1, Marco Bardelli1, Cristiana Barreca1, Francesca Bellisai1, Marta Fabbroni1, Paolo Falsetti1, Anna Paola Pata1, Enrico Selvi1, Jurgen Sota1, Antonio Vitale1, Luca Cantarini1, Bruno Frediani1, Stefano Gentileschi1 | U.O.C. Reumatologia, Dipartimento di Scienze Mediche, Chirurgiche e Neuroscienze, Università di Siena, A.O.U. Senese, Italy
146 -
PO:21:021 | The eyes tell the story: a clinical case of Rosah syndrome Nicolò Sabbion1, Sofia Vitale1, Claudia Balicchia1, Barbara Troise1, Francesca Mascia1, Eleonora Bassanello2, Jacopo Croce2, Federica Maiolini2, Filippo Mazzi2, Elisa Tinazzi2, Francesca Bosello1, Simonetta Friso1, Lucia De Franceschi1 | 1Università degli Studi di Verona; 2Azienda Ospedaliera Universitaria Integrata, Verona, Italy
245 -
PO:34:207 | When the Lungs Speak in Squeaks: Chronic Bird-Related HP in SSc-ILD with Incidental Lymphoma Mariagrazia Nuara1, Marco De Pinto2, Amelia Spinella2, Stefania Cerri1|2, Enrico Clini1|2, Dilia Giuggioli1|2 | 1Università degli Studi di Modena e Reggio Emilia, Italy; 2AOU, Policlinico di Modena, Italy
12 -
PO:25:085 | Anti-MDA5 antibody syndrome, a life-threatening condition for rheumatologist and pulmonologist A case series Francesca Cozzini1|2, Cecilia Burattini1, Elena Bravi1, Chiara Nani1, Eugenio Arrigoni1, Fabia Cavallotti1, Ilaria Platè1, Marco Sebastiani1|3 | 1Ospedale Guglielmo da Saliceto Piacenza, Italy; 2Università degli studi di Modena e Reggio Emilia, Italy; 3Università degli Studi di Parma, Italy
29 -
PO:22:039 | A rare form of interstitial lung disease: granulomatous and lymphocytic interstitial lung disease Francesca Cozzini1|2, Francesco Falco1, Alberto Cavazza1, Lucia Spaggiari3, Chiara Marvisi1, Francesca Petrillo1|2, Caterina Ricordi1|2, Francesco Muratore1|2, Fabio Brandolino1, Ilaria Chiapparoli1, Carlo Salvarani1|2, Andreina Manfredi1|2 | 1IRCCS Policlinico San Matteo, UO di Reumatologia, Pavia; 2Università degli studi di Modena e Reggio Emilia, Modena, Italy
117 -
Evaluation of Th9 lymphocytes in peripheral blood of rheumatoid arthritis patients and correlation with anti-tumor necrosis factor therapy: results from an in vitro pivotal study
2054PDF: 997IL RUOLO DEI LINFOCITI TH9 NELL'ARTRITE REUMATOIDE E NELLA RISPOSTA AL TRATTAMENTO CON INFLIXIMAB.: 606 -
PO:14:193 | Dapirolizumab Pegol Demonstrated Significant Improvement in Systemic Lupus Erythematosus Disease Activity: Efficacy and Safety Results of a Phase 3 Trial Megan EB Clowse1, Marta Mosca2, David A Isenberg3, Joan T Merrill4, Thomas Dörner5, Michelle Petri6, Edward M Vital7|8, Eric F Morand9, Teri Jimenez10, Stephen Brookes11, Janine Gaiha-Rohrbach12, Christophe Martin13, Annette Nelde14, Christian Stach15 | 1Duke University - Division of Rheumatology and Immunology Durham, USA; 2University of Pisa - Rheumatology Unit, Department of Clinical and Experimental Medicine Pisa, Italy; 3University College London - Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine London, United Kingdom; 4Oklahoma Medical Research Foundation Oklahoma City, USA; 5Charité Universitätsmedizin Berlin - Department of Medicine/Rheumatology and Clinical Immunology Berlin Germany; 6Johns Hopkins University School of Medicine Baltimore, USA; 7University of Leeds - Leeds Institute of Rheumatic and Musculoskeletal Medicine Leeds, United Kingdom; 8Leeds Teaching Hospitals NHS Trust - NIHR Leeds Biomedical Research Centre Leeds, United Kingdom; 9Monash University - Centre for Inflammatory Diseases Melbourne, Australia; 10UCB Raleigh, USA; 11Biogen Maidenhead, United Kingdom; 12Biogen Cambridge, USA; 13UCB Slough, United Kingdom; 14Biogen Baar, Switzerland; 15UCB Monheim am Rhein, Germany
36 -
PO:37:260 | Mepolizumab in the treatment of patients with eosinophilic granulomatosis with polyangiitis: real-life experience from a single-center cohort Eleonora Bruschi1, Fabrizio Angeli1, Alessandro Belotti Masserini1, Stefania Bertocchi1, Silvia Breda1, Elide Lupi1, Valeria Rossi1, Tania Ubiali1, Massimiliano Limonta1 | 1ASST Papa Giovanni XXIII Bergamo Italy
137 -
CO:01:2 | BAG3 in systemic sclerosis: possible therapeutic target and biomarker for pulmonary fibrosis Claudia Iannone1|2, Margot De Marco3, Antonina Minniti1, Paola Manzo3, Angela D'Ardia3, Antonia Falco3, Liberato Marzullo3, Angela Rosato3, Maria Caterina Turco3, Roberto Caporali1|2, Nicoletta Del Papa1|2. | 1ASST G. Pini-CTO. UOC Clinica Reumatologica, Milano; 2Department of Clinical Sciences and Community Health, University of Milano; 3Department of Medicine, Surgery and Dentistry Schola Medica Salernitana, Baronissi (SA), Italy
211 -
S02:5 | Combined anti-IL-5/IL-5r and dupilumab therapy in eosinophilic granulomatosis with polyangiitis: a European retrospective study Miriam Guerini1, Pavel Novikov2, Roberto Padoan3, Georgina Espigol Frigolé4, Jan Willem Cohen Tervaert5, Vincent Grobost6, Laurent Guilleminault7, Jan Walter Schroeder8, Bernhard Hellmich9, Joana Martins Martinho10, Camillo Ribi11, Matthieu Groh12, Benjamin Terrier13. | 1IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy; 2Sechenov University, Moscow, Russia; 3University of Padova, Padova, Italy; 4Hospital Clinic, University of Barcelona, Barcelona, Spain; 5University of Alberta, Edmonton, Canada; 6CHU Estaing Clermont-Ferrand France; 7Toulouse University Toulouse France; 8ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy; 9Medius Kliniken Kirchheim-Teck Germany; 10ULS Santa Maria, Lisbon, Portugal; 11Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; 12Hopital Foch, Suresnes, France; 13Service de Medecine interne, Hopital Cochin, AP-HP, Paris, France.
181 -
PO:29:144 | Refractory localized pain in fibromyalgia and the importance of differential diagnosis: two cases of Bertolotti’s syndrome and avascular necrosis successfully treated with targeted therapy Andrea Lacarpia1, Riccardo Terribili1, Silvia Valentini1, Marta Fabbroni1, Stefano Barbagli1, Stefano Gentileschi1, Caterina Baldi1, Luca Cantarini1, Bruno Frediani1 | 1Azienda Ospedaliera Universitaria Senese, Università degli Studi di Siena, Italy
143 -
PO:01:004 | Real-world retention of IL-17 inhibitors in psoriatic arthritis: impact of prior IL-17 exposure across multiple treatment lines in the “BIRRA” multicentre cohort Valentino Paci1, Alarico Ariani2, Eleonora Celletti3, Alberto Lo Gullo4, Camilla Mazzanti5, Valeria Nucera6, Natalia Mansueto7, Rosalba Caccavale8, Patrizia Del Medico9, Antonella Farina10, Palma Scolieri11, Cecilia Giampietro12, Olga Addimanda13, Riccardo Bixio14, Maddalena Larosa15, Viviana Ravagnani16, Federica Lumetti17, Aldo Biagio Molica Colella17, Elena Bravi17, Rosetta Vitetta17, Bernd Raffeiner17, Gilda Sandri18, Rosario Foti19, Simone Parisi20, Michele Maria Luchetti Gentiloni1, Gianluca Moroncini1. | 1Clinical Medicine, Department of Clinical and Molecular Sciences, Marche Polytechnic University, AOU delle Marche, Ancona, Italy; 2Internal Medicine and Rheumatology Unit, University Hospital of Parma, Parma, Italy; 3Rheumatology Unit, Clinica Medica Institute, Ospedale SS. Annunziata di Chieti, G.d'Annunzio University of Chieti, Chieti, Italy; 4Rheumatology Unit, ARNAS Garibaldi di Catania, Catania, Italy; 5Center for the Diagnosis and Therapy of Autoimmune Rheumagological Diseases, Ospedale Santa Rosa, ASL Viterbo Viterbo Italy; 6Rheumatology Outpatient Unit, ASL Novara, Novara, Italy; 7Ambulatori di Reumatologia ASL1 Liguria, Imperia Hospitall Imperia Italy; 8Department of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Polo Pontino, Roma, Italy; 9Rheumatology outpatient clinic - Internal Medicine Unit, Civitanova Marche Hospital, Civitanova Marche, Italy; 10Internal Medicine Unit, Rheumatology outpatient clinic, Ospedale A. Murri di Fermo, Fermo, Italy; 11Department of Medical Specialties, Nuovo Regina Margherita Hospital, Rome, Roma, Italy; 12Rheumatology Outpatient Clinic, Azienda ULSS 6 Euganea, Padova, Padova, Italy; 13Rheumatology Unit, Azienda Unità Sanitaria Locale di Bologna -- Policlinico S.Orsola- AOU di Bologna, Bologna, Italy; 14Rheumatology Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy; 15Division of Rheumatology - Medical Specialties Department, Ospedale La Colletta-Azienda Sanitaria Locale 3, Genova, Italy; 16Rheumatology Unit, Santa Chiara Hospital APSS Trento Italy; 17BIRRA - BIologic Retention Rate in chronic Arthritis - study group, Parma, Italy; 18Rheumatology Unit, University of Modena and Reggio Emilia, Modena, Italy; 19Rheumatology Unit, Policlinico San Marco Hospital, Catania, Italy; 20Rheumatology Department, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
194 -
PO:07:111 | Worsening of patient-reported outcomes is an early predictor of disease flare in patients with rheumatoid arthritis in course of treatment with conventional synthetic disease modifying anti-rheumatic drugs Ludovico De Stefano1|2, Federica Sabatelli1|2, Clelia Zampaglione1|2, Blerina Xoxi2, Antonio Manzo1|2, Carlomaurizio Montecucco1|2, Serena Bugatti1|2. | 1Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy; 2Division of Rheumatology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
135 -
PO:01:006 | Increased risk of cancer recurrence or mortality associated with DMARDs? Laura Scagnellato1, Giacomo Cozzi1, Mariagrazia Lorenzin1, Mariangela Salvato1, Alessandro Giollo1, Bernd Raffeiner1, Antonia Calligaro1, Teresa Del Ross1, Sara Bindoli1, Margherita Zen1, Paolo Sfriso1, Andrea Doria1, Roberta Ramonda1. | 1UOC Reumatologia, Dipartimento di Medicina dei Sistemi DIMED, Ospedale Università di Padova, Padova, Italy.
159 -
PO:07:108 | Achievement of Treatment Targets and Maintenance of Response with Upadacitinib in Patients with Moderate-to-Severe Rheumatoid Arthritis in a Real-world Setting: Final 2-year Outcomes from the UPHOLD Study Enrico Marchetta1, Andrew Östör2|8, Eugen Feist3, Prodromos Sidiropoulos4, Jérôme Avouac5, Martin Rebella6|7, Rajaie Namas9, Erin Mcdearmon Blondell10, Ivan Lagunes10, Tianming Gao10, Tim Shaw10, Suzan Attar11 | 1AbbVie Srl Roma, Italy; 2Monash University and Emeritus Research, Melbourne, Victoria, Melbourne, Australia; 3Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Vogelsang Gommern, Germany; 4Faculty of Medicine, University of Crete, Heraklion, Heraklion, Greece; 5Service de Rhumatologie, Hôpital Cochin, AP HP Centre Université Paris Cité, Parigi, France; 6Departamento de Medicina, Facultad de Medicina, Universidad de la República, Montevideo, Montevideo, Uruguay; 7Unidad de Enfermedades Autoinmunes Sistémicas, MUCAM, Montevideo, Montevideo, Uruguay; 8Australian National University, Camberra, Australia; 9Medical Subspecialties Institute, Division of Rheumatology, Cleveland Clinic Abu Dhabi, United Arab Emirates; 10AbbVie Inc., North Chicago, Illinois, United States of America Chicago, USA; 11King Abdulaziz University, Jeddah, Saudi Arabia
16 -
PO:11:175 | Dermatomyositis and immunosuppressant treatment: a case of Staphylococcus aureus pneumonia in a hospitalized patient Simona Fichera1, Andrea Cito1, Martina Vigilia1, Maria Morrone1, Teresa Caferri1, Crescenzio Scioscia1, Simone Perniola1, Giuseppe Lopalco1, Florenzo Iannone1. | 1Unit of Rheumatology, Department of Precision and Regenerative Medicine, Area Jonica, University of Bari, Bari, Italy.
132 -
PO:26:087 | Rituximab versus glucocorticoids for IgG4-related disease: a European retrospective multi-center study of 167 patients Marco Lanzillotta1, Jens Vikse2, Elisabetta Goni3, Jasmin Mahajne1, Veronica Batani1, Lorenzo Dagna1, Emanuel Della-Torre1 | 1Unit of Immunology, Rheumatology, Allergy, and Rare Disease, IRCCS Ospedale san Raffaele Milano, Italy; 2Department of Rheumatology, Stavanger University Hospital, Stavanger, Norway; 3Department of Medicine II, University Hospital, Ludwig Maximilian University Munich, Munich Germany
46 -
PO:35:233 | Tocilizumab is associated with improved relapse-free survival in polymyalgia rheumatica: a multicentre retrospective study Milena Bond1, Giovanni Adami2, Marianna Tamussin3, Mario Frasca4, Sara Zandonella Callegher1, Marcello Govoni3, Maurizio Rossini2, Lorenzo Dagna4, Marco Matucci Cerinic4, Christian Dejaco1, Alessandro Tomelleri4 | 1Department of Rheumatology, Brunico Hospital ASAA-SABES, Teaching Hospital of the Paracelsius Medical University Bunico, Italy; 2Rheumatology Unit, University of Verona, Policlinico Borgo Roma Verona, Italy; 3Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna Ferrara, Italy; 4Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital Milano, Italy
16
